Rafael Miguel Sábio

Dr. Rafael Miguel Sábio

Unesp, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
ASAline Martins dos Santos
Aline Martins dos Santos
SCSuzana Gonçalves Carvalho
Suzana Gonçalves Carvalho
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
RSRafael Miguel Sábio
Rafael Miguel Sábio
MGMaria Palmira Daflon Gremião
Maria Palmira Daflon Gremião
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RSRafael Miguel Sábio
Rafael Miguel Sábio
AMAndréia B. Meneguin
Andréia B. Meneguin
TRTais de Cassia Ribeiro
Tais de Cassia Ribeiro
RSRobson Silva
Robson Silva
Marlus ChorilliMarlus Chorilli
Marlus Chorilli

1 October 2018 in Industrial Crops and Products
Verified
Journal Article
Closed access
RMRachel T.A. Machado
Rachel T.A. Machado
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
RSRafael Miguel Sábio
Rafael Miguel Sábio
DFDouglas Faza Franco
Douglas Faza Franco
SASelma G. Antonio
Selma G. Antonio
HBHernane S. Barud
Hernane S. Barud

7 September 2020 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
GCGabriela Corrêa Carvalho
Gabriela Corrêa Carvalho
RSRafael Miguel Sábio
Rafael Miguel Sábio
TRTais de Cássia Ribeiro
Tais de Cássia Ribeiro
AMAndreia Sofia Monteiro
Andreia Sofia Monteiro
DPDaniela Vassalo Pereira
Daniela Vassalo Pereira
MCMarlus Chorilli
Marlus Chorilli

19 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRTais de Cassia Ribeiro
Tais de Cassia Ribeiro
RSRafael Miguel Sábio
Rafael Miguel Sábio
MLMarcela Tavares Luiz
Marcela Tavares Luiz
Lucas Canto-de-SouzaLucas Canto-de-Souza
Lucas Canto-de-Souza
BFBruno Fonseca-Santos
Bruno Fonseca-Santos
Marlus ChorilliMarlus Chorilli
Marlus Chorilli
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by cognitive and behavioral impairment. Curcumin-loaded mesoporous silica nanoparticles (MSN-CCM) can overcome the drawbacks related to the free curcumin (CCM) clinical application, such as water insolubility and low bioavailability, besides acting over the main causes associated to AD. A thermo-responsive hydrogel is an interesting approach for facilitating the administration of the nanosystem via a nasal route, as well as for overcoming mucociliary clearance mechanisms. In light of this, MSN-CCM were dispersed in the hydrogel and evaluated through in vitro and in vivo assays. The MSNs and MSN-CCM were successfully characterized by physicochemical analysis and a high value of the CCM encapsulation efficiency (EE%, 87.70 ± 0.05) was achieved. The designed thermo-responsive hydrogel (HG) was characterized by rheology, texture profile analysis, and ex vivo mucoadhesion, showing excellent mechanical and mucoadhesive properties. Ex vivo permeation studies of MSN-CCM and HG@MSN-CCM showed high permeation values (12.46 ± 1.08 and 28.40 ± 1.88 μg cm−2 of CCM, respectively) in porcine nasal mucosa. In vivo studies performed in a streptozotocin-induced AD model confirmed that HG@MSN-CCM reverted the cognitive deficit in mice, acting as a potential formulation in the treatment of AD.

1 March 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
AMAndréia Bagliotti Meneguin
Andréia Bagliotti Meneguin
ASAmanda Letícia Polli Silvestre
Amanda Letícia Polli Silvestre
LSLarissa Sposito
Larissa Sposito
MSMaurício Palmeira Chaves de Souza
Maurício Palmeira Chaves de Souza
RSRafael Miguel Sábio
Rafael Miguel Sábio
MCMarlus Chorilli
Marlus Chorilli